A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity

Cell Reports

Volumn 7, Issue 1, 2014, Pages 236-248

  Lux, Anja ^a   Seeling, Michaela ^a   Baerenwaldt, Anne ^a   Lehmann, Birgit ^a   Schwab, Inessa ^a   Repp, Roland ^b   Meidenbauer, Norbert ^c   Mackensen, Andreas ^c   Hartmann, Arndt ^c   Heidkamp, Gordon ^c   Dudziak, Diana ^c   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Klinikum Am Bruderwald   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD20 ANTIGEN; FC RECEPTOR; FC RECEPTOR IA; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; GENOMIC DNA; IMMUNOGLOBULIN G; RAG2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL POPULATION; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; B LYMPHOCYTE; IMMUNOLOGY;

ANIMALIA; MURINAE; MUS; PRIMATES;

ANIMALS; B-LYMPHOCYTES; BONE MARROW; HUMANS; IMMUNOGLOBULIN G; MICE; MODELS, ANIMAL; RECEPTORS, IGG;

EID: 84898045276     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.02.041     Document Type: Article

References (60)

1. Baerenwaldt A., Lux A., Danzer H., Spriewald B.M., Ullrich E., Heidkamp G., Dudziak D., Nimmerjahn F. Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system invivo. Proc. Natl. Acad. Sci. USA 2011, 108:18772-18777.
2. Baudino L., Nimmerjahn F., Azeredo da Silveira S., Martinez-Soria E., Saito T., Carroll M., Ravetch J.V., Verbeek J.S., Izui S. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J.Immunol. 2008, 180:1948-1953.
3. Beers S.A., Chan C.H., James S., French R.R., Attfield K.E., Brennan C.M., Ahuja A., Shlomchik M.J., Cragg M.S., Glennie M.J. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008, 112:4170-4177.
4. Beers S.A., French R.R., Chan H.T., Lim S.H., Jarrett T.C., Vidal R.M., Wijayaweera S.S., Dixon S.V., Kim H., Cox K.L., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010, 115:5191-5201.
5. Biburger M., Nimmerjahn F. Low level of FcγRIII expression on murine natural killer cells. Immunol. Lett. 2012, 143:53-59.
6. Biburger M., Aschermann S., Schwab I., Lux A., Albert H., Danzer H., Woigk M., Dudziak D., Nimmerjahn F. Monocyte subsets responsible for immunoglobulin G-dependent effector functions invivo. Immunity 2011, 35:932-944.
7. Blom B., Spits H. Development of human lymphoid cells. Annu. Rev. Immunol. 2006, 24:287-320.
8. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007, 26:3629-3636.
9. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daëron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725.
10. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343-357.
11. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
12. Fossati-Jimack L., Ioan-Facsinay A., Reininger L., Chicheportiche Y., Watanabe N., Saito T., Hofhuis F.M., Gessner J.E., Schiller C., Schmidt R.E., et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact invivo with the low-affinity Fcgamma receptor III. J.Exp. Med. 2000, 191:1293-1302.
13. Ghia P., ten Boekel E., Rolink A.G., Melchers F. B-cell development: a comparison between mouse and man. Immunol. Today 1998, 19:480-485.
14. Goldman J.P., Blundell M.P., Lopes L., Kinnon C., Di Santo J.P., Thrasher A.J. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br. J. Haematol. 1998, 103:335-342.
15. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., Lin W.Y., Hu Z., Lu Y., Chen Y., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J.Immunol. 2005, 174:817-826.
16. Hamaguchi Y., Uchida J., Cain D.W., Venturi G.M., Poe J.C., Haas K.M., Tedder T.F. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J.Immunol. 2005, 174:4389-4399.
17. Hamaguchi Y., Xiu Y., Komura K., Nimmerjahn F., Tedder T.F. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J.Exp. Med. 2006, 203:743-753.
18. Hirano M., Davis R.S., Fine W.D., Nakamura S., Shimizu K., Yagi H., Kato K., Stephan R.P., Cooper M.D. IgEb immune complexes activate macrophages through FcgammaRIV binding. Nat. Immunol. 2007, 8:762-771.
19. Hogarth P.M. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 2002, 14:798-802.
20. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
21. Johnson T.A., Press O.W. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann. Hematol. 2000, 79:175-182.
22. Kaneko Y., Nimmerjahn F., Madaio M.P., Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J.Exp. Med. 2006, 203:789-797.
23. Kasperkiewicz M., Nimmerjahn F., Wende S., Hirose M., Iwata H., Jonkman M.F., Samavedam U., Gupta Y., Möller S., Rentz E., et al. Genetic identification and functional validation of FcγRIV as key molecule in autoantibody-induced tissue injury. J.Pathol. 2012, 228:8-19.
24. Legrand N., Weijer K., Spits H. Experimental model for the study of the human immune system: production and monitoring of "human immune system" Rag2-/-gamma c-/- mice. Methods Mol. Biol. 2008, 415:65-82.
25. Legrand N., Ploss A., Balling R., Becker P.D., Borsotti C., Brezillon N., Debarry J., de Jong Y., Deng H., Di Santo J.P., et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 2009, 6:5-9.
26. Li Y., Chen Q., Zheng D., Yin L., Chionh Y.H., Wong L.H., Tan S.Q., Tan T.C., Chan J.K., Alonso S., et al. Induction of functional human macrophages from bone marrow promonocytes by M-CSF in humanized mice. J.Immunol. 2013, 191:3192-3199.
27. Lux A., Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 2011, 780:113-124.
28. Lux A., Nimmerjahn F. Of mice and men: the need for humanized mouse models to study human IgG activity invivo. J.Clin. Immunol. 2013, 33(Suppl 1):S4-S8.
29. Lux A., Yu X., Scanlan C.N., Nimmerjahn F. Impact of immunecomplex size and glycosylation on IgG binding to human FcγRs. J.Immunol. 2013, 190:4315-4323.
30. Mancardi D.A., Iannascoli B., Hoos S., England P., Daëron M., Bruhns P. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J.Clin. Invest. 2008, 118:3738-3750.
31. Mancardi D.A., Jönsson F., Iannascoli B., Khun H., Van Rooijen N., Huerre M., Daëron M., Bruhns P. Cutting Edge: The murine high-affinity IgG receptor FcγRIV is sufficient for autoantibody-induced arthritis. J.Immunol. 2011, 186:1899-1903.
32. Montalvao F., Garcia Z., Celli S., Breart B., Deguine J., Van Rooijen N., Bousso P. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J.Clin. Invest. 2013, 123:5098-5103.
33. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J.Clin. Oncol. 2008, 26:1789-1796.
34. Nakashima T., Hayashi M., Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol. Metab. 2012, 23:582-590.
35. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
36. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
37. Nimmerjahn F., Bruhns P., Horiuchi K., Ravetch J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 2005, 23:41-51.
38. Nimmerjahn F., Lux A., Albert H., Woigk M., Lehmann C., Dudziak D., Smith P., Ravetch J.V. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity invivo. Proc. Natl. Acad. Sci. USA 2010, 107:19396-19401.
39. Otten M.A., van der Bij G.J., Verbeek S.J., Nimmerjahn F., Ravetch J.V., Beelen R.H., van de Winkel J.G., van Egmond M. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J.Immunol. 2008, 181:6829-6836.
40. Ravetch J.V., Nimmerjahn F. Fc receptors. Fundamental Immunology 2008, Lippincott-Raven, Philadelphia. Fifth Edition. W.E. Paul (Ed.).
41. Sanz I., Lee F.E. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337.
42. Sanz I., Anolik J.H., Looney R.J. B cell depletion therapy in autoimmune diseases. Front. Biosci. 2007, 12:2546-2567.
43. Seeling M., Hillenhoff U., David J.P., Schett G., Tuckermann J., Lux A., Nimmerjahn F. Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc. Natl. Acad. Sci. USA 2013, 110:10729-10734.
44. Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-1652.
45. Shultz L.D., Brehm M.A., Garcia-Martinez J.V., Greiner D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 2012, 12:786-798.
46. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010, 10:328-343.
47. Smith P., DiLillo D.J., Bournazos S., Li F., Ravetch J.V. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 2012, 109:6181-6186.
48. St Clair E.W. Novel targeted therapies for autoimmunity. Curr. Opin. Immunol. 2009, 21:648-657.
49. Syed S.N., Konrad S., Wiege K., Nieswandt B., Nimmerjahn F., Schmidt R.E., Gessner J.E. Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a. Eur. J. Immunol. 2009, 39:3343-3356.
50. Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002, 2:580-592.
51. Tanaka S., Saito Y., Kunisawa J., Kurashima Y., Wake T., Suzuki N., Shultz L.D., Kiyono H., Ishikawa F. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice. J.Immunol. 2012, 188:6145-6155.
52. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
53. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., Tedder T.F. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J.Exp. Med. 2004, 199:1659-1669.
54. Uchida J., Lee Y., Hasegawa M., Liang Y., Bradney A., Oliver J.A., Bowen K., Steeber D.A., Haas K.M., Poe J.C., Tedder T.F. Mouse CD20 expression and function. Int. Immunol. 2004, 16:119-129.
55. van der Bij G.J., Bögels M., Otten M.A., Oosterling S.J., Kuppen P.J., Meijer S., Beelen R.H., van Egmond M. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J.Hepatol. 2010, 53:677-685.
56. Waldmann T.A. Immunotherapy: past, present and future. Nat. Med. 2003, 9:269-277.
57. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
58. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J.Clin. Oncol. 2003, 21:3940-3947.
59. Weng W.K., Czerwinski D., Timmerman J., Hsu F.J., Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J.Clin. Oncol. 2004, 22:4717-4724.
60. Yazawa N., Hamaguchi Y., Poe J.C., Tedder T.F. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl. Acad. Sci. USA 2005, 102:15178-15183.